Header

Skip to main content

Rockville Named One of the “7 Best Places To Live In Maryland In 2026”

Rockville exemplifies many of the key qualities that make Maryland communities great places to live

Rockville, Maryland has been named one of Maryland’s “Best Places to Live” for a second year in a row by WorldAtlas, one of the largest publishing resources in geography and related topics including sociology, demography, environment, economics, politics, and travel. This recognition reflects Rockville’s ongoing commitment to quality of life, economic opportunity, and vibrant community living.

According to WorldAtlas, Rockville exemplifies many of the key qualities that make Maryland communities great places to live:

  • Strong employment base and economic connectivity: Rockville is part of one of Maryland’s most dynamic job corridors with direct Metro access to Washington, D.C., and deep concentrations of federal agencies, healthcare, biotech, and tech employers.

  • High-performing public schools: The excellence of Rockville’s schools continues to be a draw for families and new residents alike.

  • Transit and infrastructure: Multiple Red Line Metro stations make commuting easy, while reliable local infrastructure supports everyday living and long-term growth.

  • Parks and outdoor lifestyle: With Rock Creek Regional Park on its doorstep and miles of trails, lakes, and green space, Rockville offers outdoor access that enriches daily life — not just weekend recreation.

  • A vibrant downtown: Rockville Town Square serves as a true civic and cultural center, bringing people together for everything from dining and shopping to public events and seasonal festivities.

Per WorldAtlas, Rockville is “a common choice for families and professionals” due to its powerful combination of community amenities, access, and infrastructure that supports a high quality of life. Rockville continues to grow and evolve while staying true to the qualities that make it special — strong neighborhoods, thriving local businesses, accessible transit, and a welcoming community for residents of all ages and backgrounds. This latest accolade follows other recent rankings that highlight Rockville’s strength as both a place to live and work; U.S. News & World Report also ranked Rockville among the top places to live in Maryland for 2025–2026, underscoring the city’s balanced lifestyle, economic opportunity, and quality amenities.

To read the entire list from WorldAtlas, click here: https://www.worldatlas.com/cities/8-best-places-to-live-in-maryland-2025.html 

Maryland Women’s Business Center Recognized as 2026 National WBC of Excellence

The Association of Women's Business Center's recognition highlights MWBC’s commitment to impact, innovation, and service

Rockville, Md., – The Maryland Women’s Business Center (MWBC) is honored to be recognized for graduating in the 2026 cohort with the National WBC of Excellence program offered by the Association of Women’s Business Centers (AWBC). This marks the second consecutive year MWBC has earned the National WBC of Excellence designation. 

The primary objective of the National Women’s Business Center of Excellence designation is to recognize organizations that demonstrate commitment and efficacy of the mission, vision, and values of their Women’s Business Center thereby achieving the greatest outcomes for women-owned businesses.

“I am beyond proud of our 2026 Women’s Business Center of Excellence graduates! Their hard work, focus, and passion for serving women entrepreneurs shine through in every aspect of their operations,” says Klassi Duncan, AWBC Board Chair and Vice President of the Center for Entrepreneurship & Innovation (CEI) at the Urban League of Louisiana. “Their dedication to excellence will continue to uplift and accelerate the success of women-owned businesses nationwide.”

Over the course of six milestone assignments, WBCs partnered with a peer in their cohort to identify gaps and opportunities for the WBC to improve in a variety of areas; including strategic goal-setting, service delivery, continuous improvement and/or peer relationships. In order to fulfill these objectives, AWBC recognizes the value of the organization’s volunteers, leadership team and funders which is reflected in the involvement of these stakeholders in the final stages of the designation attainment.

“MWBC continually evolves to meet the needs of entrepreneurs and incorporate best practices, including maintaining our designation as a WBC of Excellence,” said Karen Sippel, MWBC Managing Director. “This process strengthens how we serve our clients, and this work directly translates to better outcomes for the business owners we support.”

The National WBC of Excellence graduation and closing ceremony took place on December 12, 2025. For more information about MWBC resources, please visit marylandwbc.org.  

About Maryland Women’s Business Center

Maryland Women’s Business Center (MWBC) is a signature program of Rockville Economic Development, Inc. MWBC helps entrepreneurs and small business owners across Maryland’s Capital Region start, sustain, and grow their companies. Through workshops, one-on-one counseling, facilitated peer group support, and access to capital, MWBC annually helps over 1,500 entrepreneurs gain the skills, connections, and confidence necessary to navigate entrepreneurship. Learn more at marylandwbc.org.

About The Association of Women’s Business Centers

The Association of Women’s Business Centers (AWBC) is a non-profit 501(c)(3) organization founded in 1998 to support the national network of Women’s Business Centers (WBC) with programming and advocacy. The AWBC works to secure economic and entrepreneurial opportunities for women by supporting and sustaining a national network of over 152 Women’s Business Centers (WBC) in every State in the U.S. and Puerto Rico. WBCs have more than 30-years of success in providing educational training, mentoring, free business counseling, business development, and financing opportunities to over 150,000 women entrepreneurs and small businesses each year. The WBC program is a public-private partnership with the U.S. Small Business Administration. To learn more about AWBC visit www.awbc.org.

Samsung Biologics expands U.S. manufacturing capabilities with strategic acquisition of Human Genome Sciences from GSK

Aerial view of commercial buildings with two highlighted
Aerial view of cGMP manufacturing plants - Image credit: Samsung Biologics

Samsung Biologics will acquire the Rockville assets for $280 million and will also retain more than 500 employees

Incheon, S. KOREA, Maryland, United States, London, UK, December 22, 2025 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

Located in Rockville, Maryland, the facility sits at the center of one of the key U.S. bio-clusters and encompasses two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, and Samsung Biologics plans to make additional investments to expand the site’s capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines.

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for USD 280 million. The company will also retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into our global network, Samsung Biologics will provide clients with flexible, multi-site options in both the U.S. and Korea to ensure that live-saving therapeutics are reliably available to American patients.

Samsung Biologics has established a proven track record of operational and construction excellence through on-time completion of its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programs for new modalities. With 785,000 liters of capacity across five plants, the industry’s leading capacity, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies.

“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said John Rim, CEO and President of Samsung Biologics. “This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.”

Regis Simard, President, Global Supply Chain, GSK, said: “Today’s agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK’s supply chain resilience. Along with GSK’s recent commitment to invest $30bn in R&D and manufacturing in the US over the next 5 years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site.”

About Samsung Biologics

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions – from cell line development to final aseptic fill/finish – as well as comprehensive laboratory testing services at every stage of biopharmaceutical products. Learn more at samsungbiologics.com

Press release orginally published by Samsung Biologics: https://samsungbiologics.com/media/company-news/samsung-biologics-expands-u-s–manufacturing-capabilities-with-strategic-acquisition-from-gsk

Rockville’s Rise Therapeutics receives TEDCO SBIR/STTR Matching Funds

Rise Therapeutics is developing first-in-class oral immune biomodulators for the treatment of autoimmune diseases and cancer.

Rise Therapeutics, a clinical-stage immunotherapy company headquartered in Rockville’s Biotech Corridor, was among 13 Maryland companies to receive funding through TEDCO’s latest SBIR/STTR Matching Funds awards. The program distributed $875,000 across two rounds, with 11 companies, including Rise Therapeutics who received $75,000 in Phase II matching funds.

The SBIR/STTR Matching Funds program strengthens the impact of federal Small Business Innovation Research and Small Business Technology Transfer awards by providing supplemental state funding to promote commercialization and job creation.

Rise Therapeutics is developing first-in-class oral immune biomodulators for the treatment of autoimmune diseases and cancer. Unlike traditional biological therapies requiring injection or infusion, the company’s proprietary platform delivers targeted protein therapy through oral capsules. Rise currently has four programs in clinical testing, including therapies for ulcerative colitis, rheumatoid arthritis, Sjögren’s disease, and cancer.

The company operates a GMP manufacturing facility in Rockville and has previously received TEDCO Seed Funds investment as well as NIH funding to support its clinical development.

Learn more about TEDCO’s SBIR/STTR Matching Funds program at tedcomd.com/funding/federal-programs/sbirsttr-matching-funds

About Rise Therapeutics

Rise Therapeutics is a clinical-stage immunotherapy company developing first-in-class Oral Immune Biomodulators, for the treatment of autoimmune diseases and cancer. With a fully integrated research and product development infrastructure, the team leverages innovative scientific discoveries to drive novel drug development through human clinical proof-of-concept. Learn more at risetherapeutics.com

About TEDCO

TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at www.tedcomd.com

Seventeen Rockville companies awarded Montgomery County Technology Innovation and Founders Fund grants

The recipients span industries that drive growth in the region including life sciences, technology, clean energy, and AI.

Seventeen Rockville-based companies are among the fifty-five Montgomery County businesses selected to receive grants through the County’s Technology Innovation Fund and Founders Fund programs. The awards, totaling $7.5 million across all recipients, support early-stage companies working to commercialize proprietary technologies and bring innovative products to market.

Rockville awardees represent a strong cross-section of the city’s entrepreneurial ecosystem, with fifteen companies receiving Technology Innovation Fund grants and two companies awarded Founders Fund grants. The recipients span industries that drive growth in the region including life sciences, technology, clean energy, and AI.

About the Grant Programs

Montgomery County launched the Technology Innovation Fund and Founders Fund in late 2024, making funding available to support high-growth small businesses throughout the county.

The Technology Innovation Fund provides grants to early-stage businesses developing proprietary technology with high growth potential. The fund supports commercialization projects that help innovative products move closer to market and achieve significant business milestones.

The Founders Fund offers grants to early-stage entrepreneurs from historically underrepresented communities who face systemic barriers to accessing capital. Eligibility is assessed using Montgomery Planning’s Community Equity Index along with state and federal certification tools for minority, women, and veteran-owned businesses.

The programs were executed through a partnership among the Office of the County Executive, Montgomery County Economic Development Corporation (MCEDC), and the County’s Department of Finance. Applications were evaluated by FedTech, an independent third-party organization specializing in connecting innovative technologies to commercial markets.

Companies receive an initial disbursement of funds and will receive a second payment once their commercialization milestones have been completed.

Rockville Technology Innovation Fund Awardees

AkriVita – Life Sciences. AkriVita develops 3D-printed microcapillary needles that deliver precision and reliability in microinjection to accelerate discoveries, prevent and treat disease, and help create life.

Cellepus Therapeutics – Life Sciences. Cellepus is developing off-the-shelf CAR T Cells by engineering cord blood–derived γδ T cells with a first-in-class NKG2D-based signaling architecture, targeting them to solid tumors with novel tumor-specific antigens.

EasyScaleCloud – Technology. EasyScaleCloud is an AI, data, and cloud solutions company building a diversified portfolio of specialized AI products.

EzVal Inc. – Technology. EzVal Inc. is developing a paperless validation platform with strengthened cloud infrastructure to deliver greater value to biotech and life-science organizations.

Gutz Analytics LLC – Life Sciences. Gutz Analytics is a multi-omics AI company integrating microbiome, metabolome, and other molecular datasets to build predictive models that support clinical trials and companion diagnostics.

Healable – Life Sciences. Healable empowers healthcare providers with secure, AI-driven tools that enhance peer consultations and improve patient outcomes.

LEGIT (LensGuided Imaging Technology) – Life Sciences. LEGIT is developing a nanophotonic imaging platform for in vivo imaging with minimal damage.

Liatris – Life Sciences. Liatris is an advanced materials company developing high-performance and resilient thermal insulation products for energy efficiency, including state-of-the-art pilot manufacturing capabilities in Rockville.

LoBio, Inc. – Life Sciences. LoBio is a medtech company commercializing a patented at-home plasma collection device that enables clinical-grade plasma collection and safer, more reliable decentralized blood testing.

Lumo Imaging – Life Sciences. Lumo Imaging is developing an AI-driven total body cancer screening system with the potential to expand dermatological access to underserved areas.

Magic Shell Software – Technology. Magic Shell Software builds military-grade security for embedded systems, providing anti-tamper and intellectual property protection for aerospace, IoT, and government customers.

Pediametrix Inc. – Life Sciences. Pediametrix is a medical device startup behind SoftSpot®, the only FDA-cleared mobile app that helps pediatric clinicians and parents measure and monitor infant head shape and growth.

Pirl Technology – Clean Energy. Pirl Technology is dedicated to empowering small and medium-sized businesses to profitably provide electric vehicle (EV) charging as a service to their customers.

Prophiotrics LLC – Life Sciences. Prophiotrics is developing a pioneering bacteriophage-based acne treatment that selectively eliminates Cutibacterium acnes while preserving and supporting the skin’s natural microbiome.

VascRisk LLC – Life Sciences. VascRisk combines smart technology with personalized care to provide early detection, precise prediction, and effective reversal strategies for vascular health.

Rockville Founders Fund Awardees

Ant Technology – Technology. Ant Technology leverages AI to advance the real estate industry by streamlining processes, enhancing decision-making, and unlocking new opportunities for businesses and individuals in the property market.

Wintreatments Holdings, LLC – Technology. Wintreatments Holdings specializes in developing and commercializing smart window treatment solutions designed to enhance energy efficiency, privacy, and automation.

Rockville ranks among America’s most livable communities in 2025

Rockville has earned national recognition as one of the most livable mid-size communities in the United States, according to the newly released 2025 AARP Livability Index.

The city ranked #5 among mid-size communities (population 25,000-99,999) nationwide, joining an elite group of cities recognized for services and amenities that improve residents’ quality of life. Montgomery County also placed #2 among very large communities (population 500,000+), trailing only San Francisco.

The AARP Livability Index evaluates communities across seven categories: housing, neighborhood, transportation, environment, health, engagement, and opportunity. The tool draws from more than 50 national data sources and measures 61 indicators of livability—from monthly housing costs and environmental quality to opportunities for social connections and age-friendly planning.

The city’s strong transit connectivity, walkable neighborhoods, access to healthcare facilities, and robust community engagement all contribute to its high score. For businesses considering where to locate or expand, these livability factors directly translate to talent attraction and workforce retention advantages.

Explore AARP’s Livability Index Tool: https://livabilityindex.aarp.org/

Rockville scores top marks again for commitment to LGBTQ+ community

The annual ranking highlights cities that advance health, welfare, and equal treatment for their LGBTQ+ communities.

Rockville has scored 100 marks for the city’s commitment to the health, welfare, safety and equality of its lesbian, gay, bisexual, transgender and queer community. 

This is the city’s eighth year of participation in the Human Rights Campaign’s (HRC) Municipal Equality Index (MEI) and the 14th year for MEI’s annual report. 

Rockville scored 99 out of 100, plus an additional bonus point, for its nondiscrimination laws, law enforcement, employment and workplace inclusivity, leadership and services to the LGBTQ+ community. Final scores cannot exceed 100. 

The HRC framed this year’s results against a challenging national backdrop, underscoring the work of local governments supporting their LGBTQ+ residents.  

“Cities and towns around the country are stepping up each and every day, finding new and innovative ways to empower LGBTQ+ people in the face of a dire national state of emergency. Even when anti-LBGTQ+ extremists in state capitals are working to undermine their progress, mayors and city councilmembers keep fighting to make sure that LGBTQ+ people in their communities — especially trans people — are supported and lifted up to the fullest extent possible,” stated HRC president Kelley Robinson. 

The 2025 MEI showed local government leaders’ dedication while governing in an “increasingly hostile environment,” she continued. 

The 14th annual MEI scorecard, released in mid-November, analyzes and rates 506 municipalities across the country, measuring each for the inclusivity of laws, policies and services for their LGBTQ communities. The MEI is the only nationwide assessment of municipal laws, policies and services that are inclusive of LGBTQ+ people. 

Cities rated include the 50 state capitals, the 200 largest cities in the U.S., the five largest cities or municipalities in each state, cities home to the state’s two largest public universities, 75 cities and municipalities that have high proportions of same-sex couples, and 98 cities selected by HRC and Equality Federation state groups’ members and supporters. 

Cities are rated across numerous criteria, covering citywide nondiscrimination protections, policies for municipal employees, city services, law enforcement and the city’s leadership on LGBTQ+ equality. 

Learn more about the MEI at hrc.org/MEI

Press Release originally published by The City of Rockville: https://www.rockvillemd.gov/news/2025/11/19/rockville-scores-top-marks-again-for-commitment-to-lgbtq-community-2/

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth

This investment is AstraZeneca's fourth major U.S. manufacturing investment announcement this year, advancing its $50 billion commitment to medicines manufacturing and R&D

Montgomery County, Md., Nov. 21, 2025 – AstraZeneca today announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 highly skilled jobs.

The Frederick facility currently produces biologics, a type of medication used across AstraZeneca’s portfolio of cancer, auto immune, respiratory and rare disease treatments. The planned expansion will nearly double commercial manufacturing capacity, enabling increased supply of existing medicines and, for the first time, production across the Company’s rare disease portfolio.  It will create 200 highly skilled jobs and 900 construction roles and is expected to be operational in 2029.

In parallel, AstraZeneca will build a new clinical manufacturing facility to expand its footprint in Gaithersburg.  The facility, which will be fully operational by 2029, will create an additional 100 jobs, retain 400 roles and support a further 1,000 construction-related jobs.

Both the expanded facility in Frederick and the new facility in Gaithersburg will leverage cutting-edge AI, automation and data analytics and be built to the highest environmental standards.

Maryland Governor, Wes Moore, said: “AstraZeneca’s commitment to Maryland speaks to our unique, world-class biotech ecosystem.  This landmark investment affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain, accelerating the development of life-saving therapies, and creating hundreds of jobs. We are proud to partner with AstraZeneca to grow our economy and build new pathways to work, wages, and wealth for all.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today marks a landmark moment for Maryland and American patients. As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world.”

Today’s announcement is part of AstraZeneca’s historic $50 billion investment announced in July and follows a series of US commitments over the past six months, including unveiling a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of the Company’s existing manufacturing facility in Coppell, Texas.

The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy. 

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Press Release originally published by AstraZeneca: https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-dollar2-billion-manufacturing-investment-in-maryland-supporting-2600-jobs-and-catalysing-economic-growth.html

X-Energy closes oversubscribed $700 million Series D financing round to continue expansion to meet global energy demand

New capital fuels the company’s next phase of growth in clean, reliable nuclear energy solutions.

ROCKVILLE, Md., Nov. 24, 2025 – X-Energy Reactor Company, LLC (“X-energy”), a leader in advanced nuclear reactor and fuel technology, today announced it has closed an oversubscribed Series D financing round of approximately $700 million led by Jane Street, from new investors including ARK Invest, Galvanize, Hood River Capital Management, Point72, Reaves Asset Management, XTX Ventures and various others, as well as existing investors including Ares Management funds, Corner Capital, Emerson Collective, NGP, Segra Capital Management and others.

“The response and commitment from the participants in this financing round is a strong affirmation of the role X-energy expects to play in shaping the future of energy,” said Kam Ghaffarian, Ph.D., Founder and Executive Chairman of X-energy. “When I founded X-energy, I envisioned a company that could redefine how to make advanced nuclear energy accessible, affordable, and essential to an energy abundant future. With the support of our investors, both new and existing, we are closer to realizing that vision.”

X-energy expects to utilize proceeds from the round to help continue the expansion of its supply chain and commercial pipeline, supporting an industry-leading orderbook of more than 11 GW, representing approximately 144 advanced small modular reactors.

“We are highly focused on building a world-class project and technology delivery platform to accelerate the commercialization of our Xe-100 reactor and TRISO-X fuel,” said X-energy CEO J. Clay Sell. “The success of this financing round allows us to deepen partnerships with critical deployment partners and invest in a robust and reliable supply chain to successfully deliver projects with our customers.” 

X-energy is advancing its pioneering Xe-100 advanced small modular reactor and TRISO-X fuel in projects with Dow, Amazon, and Centrica. Its initial proposed four-unit Xe-100 plant is planned for Dow Inc.’s UCC Seadrift Operations manufacturing site on the Texas Gulf Coast, supported by the U.S. Department of Energy’s Advanced Reactor Demonstration Program, and currently under permit review with the U.S. Nuclear Regulatory Commission. Following the project with Dow, X-energy and Amazon announced Amazon’s options to deploy more than 5 GW of Xe-100 projects across United States by 2039, beginning with the Cascade Advanced Energy Facility in Washington state in partnership with Energy Northwest. Additionally, X-energy is partnered with British multinational energy and services company Centrica to deploy 6 GW in the United Kingdom.

X-energy is also constructing an advanced nuclear fuel fabrication facility to manufacture its proprietary TRISO-X fuel, a first of its kind in the United States. Together, X-energy’s portfolio is designed to deliver scalable, safer, and more reliable power to meet growing global energy demand.

Advisors

Moelis & Company LLC and J.P. Morgan Securities LLC acted as placement agents for the transaction and Latham & Watkins LLP acted as legal advisor to X-energy on the transaction. 

About X-Energy

X-Energy Reactor Company, LLC, is a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation that is redefining the nuclear energy industry through its development of safer and more efficient advanced small modular nuclear reactors and proprietary fuel to deliver reliable, zero-carbon and affordable energy to people around the world. X-energy’s simplified, modular, and intrinsically safe SMR design expands applications and markets for deployment of nuclear technology and drives enhanced safety, lower cost and faster construction timelines when compared with other SMRs and conventional nuclear. For more information, visit X-energy.com.

Press Release originally published by X-Energy: https://x-energy.com/media/news-releases/x-energy-closes-oversubscribed-700-million-series-d-financing-round-to-continue-expansion-to-meet-global-energy-demand

Capital Bank Achieves its Sixth “Best Banks to Work For” Distinction

The annual ranking recognizes banks that create positive, supportive, and high-performing workplace cultures

ROCKVILLE, Md., Nov. 19, 2025 (GLOBE NEWSWIRE) — Capital Bank has again been named one of American Banker’s Best Banks to Work For in 2025. The annual ranking, conducted in partnership with Best Companies Group, recognizes banks that excel at creating positive, supportive, and high-performing workplace cultures.

This year, 90 banks nationwide earned a spot on the list based on an anonymous employee survey and a comprehensive review of each institution’s benefits, policies, and organizational practices. Capital Bank was ranked #85, marking the sixth time the Bank has received this recognition. This achievement reflects Capital Bank’s ongoing commitment to cultivating an environment where employees feel valued, supported, and empowered.

“Our culture is built on genuinely caring about our people,” said Eric Suss, Executive Vice President and Chief Human Resources Officer at Capital Bank. “We invest in programs that encourage growth, reward excellence, and strengthen collaboration. That is what keeps our teams engaged and energized.”

Capital Bank continues to prioritize employee well-being and development through initiatives focused on rewards and recognition, wellness programming, and community involvement. These efforts give employees meaningful opportunities to learn, contribute, connect, and voice their perspectives.

“Our employees drive everything we do,” said Ed Barry, CEO of Capital Bank. “We are a growth-driven company, but growth only happens when the right people are supported in the right environment. This recognition reflects the strength of our culture and the dedication of our team.”

The Bank’s signature initiative, Capital Bank Immersion, introduces new employees to senior leaders and key areas of the organization during onboarding. Following the acquisition of Integrated Financial Holdings, Inc. (IFH), the program expanded to welcome new colleagues in North Carolina, South Carolina, Indiana, and Illinois, ensuring consistency in connection and alignment across markets.

“The Best Banks to Work For represent institutions that give employees meaningful reasons to be proud of where they work,” said Chana Schoenberger, editor-in-chief of American Banker. “They understand how to create environments where people feel valued and find purpose in their roles.”

Participation in the Best Banks to Work For program involves a two-part assessment. The first part, worth approximately 25 percent of the total score, reviews each bank’s workplace policies, practices, and demographics. The second part, worth approximately 75 percent, consists of anonymous employee surveys focused on day-to-day experiences and attitudes.

To qualify, banks must have at least 50 U.S. employees and a minimum of one year in operation. Best Companies Group manages the registration, survey process, and data analysis to determine the final rankings.

About Capitol Bank

Capital Bancorp, Inc., Rockville, Maryland is a registered bank holding company incorporated under the laws of Maryland. Capital Bancorp has been providing financial services since 1999 and now operates bank branches in seven locations including Washington D.C., Reston, VA, Ft. Lauderdale, FL, Rockville, MD, Columbia, MD, Raleigh, NC, and N. Riverside, IL. Capital Bancorp had assets of approximately $3.4 billion at September 30, 2025 and its common stock is traded in the NASDAQ Global Market under the symbol “CBNK.” More information can be found at the Company’s website www.CapitalBankMD.com under its investor relations page.

Capital Bank’s personalized approach to business banking and the creative delivery of technology has helped fuel our continued growth. During all of our success, we have delivered meaningful client experiences by remaining true to a core operating principle: Think Big, Act Local.

About American Banker

American Banker empowers banking professionals with unique analysis and insight into the ideas transforming their business and industry. Across its journalism, events, research and benchmarking, it helps drive the way forward through the complexity of business innovation, retail and commercial disruption, technology, regulation and reform. With a banking community 850k strong, American Banker’s content connects leaders online, in person and in print every day.

About Best Companies Group 

Since 2004, Best Companies Group has specialized in identifying and recognizing great employers to work for. We are an independent research firm that ranks companies based on our established research methodology. Our surveys provide actionable, hard-to-obtain data that companies use to improve employee recruitment and retention.

Press Release originally published by Capital Bancorp, Inc.: https://ir.capitalbankmd.com/news-releases/news-release-details/capital-bank-achieves-its-sixth-best-banks-work-distinction